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Probenecid interacts with transport processes of drugs at several sites in the body. For most quinolones,
renal clearance is reduced by concomitant administration of probenecid. The interaction between gemifloxacin
and probenecid has not yet been studied. We studied the extent, time course, site(s), and mechanism of this
interaction. Seventeen healthy volunteers participated in a randomized, two-way crossover study. Subjects
received 320 mg gemifloxacin as an oral tablet without and with 4.5 g probenecid divided in eight oral doses.
Drug concentrations in plasma and urine were analyzed by liquid chromatography-tandem mass spectrometry.
WinNonlin was used for noncompartmental analysis, compartmental modeling, and statistics, and NONMEM
was used for visual predictive checks. Concomitant administration of probenecid increased plasma gemifloxa-
cin concentrations and amounts excreted in urine compared to baseline amounts. Data are average estimates
(percent coefficients of variation). Modeling showed a competitive inhibition of the renal tubular secretion of
gemifloxacin by probenecid as the most likely mechanism of the interaction. The estimated Km and Vmax for the
saturable part of renal elimination were 9.16 mg/liter (20%) and 113 mg/h (21%), respectively. Based on the
molar ratio, the affinity for the renal transporter was 10-fold higher for gemifloxacin than for probenecid. Since
probenecid reached an 200-times-higher area under the molar concentration-time curve from 0 to 24 h than
gemifloxacin, probenecid inhibited the active tubular secretion of gemifloxacin. Probenecid also reduced the
nonrenal clearance of gemifloxacin from 25.2 (26%) to 21.0 (23%) liters/h. Probenecid inhibited the renal
tubular secretion of gemifloxacin, most likely by a competitive mechanism, and slightly decreased nonrenal
clearance of gemifloxacin.
Gemifloxacin is a fluoronaphthyridone antimicrobial with an
enhanced activity against gram-positive pathogens (7). It is
approved by the FDA for treatment of acute bacterial exacer-
bations of chronic bronchitis and mild to moderate community-
acquired pneumonia. Renal clearance of gemifloxacin exceeds
the glomerular filtration rate, which indicates net tubular se-
cretion (2). As gemifloxacin exists primarily as a zwitterion at
physiological pH, it is likely to interact with organic anion
transporters (OATs) and organic cation transporters (OCTs)
in renal tubular cells (31). Probenecid is known to inhibit active
transport processes of anionic and cationic drug molecules at
several sites in the body (13, 15, 16). Probenecid is well docu-
mented to decrease the renal secretion of many quinolones,
e.g., gatifloxacin (21), levofloxacin (10, 11), and ciprofloxacin
(14). However, there are no reports on the interaction between
probenecid and gemifloxacin.
For studies of the time course and mechanism of a drug-
drug interaction, compartmental modeling is superior to stan-
dard noncompartmental analysis (NCA). In addition to having
other limitations, standard NCA does not allow one to predict
the interaction for other dosage regimens of the drug plus
inhibitor which might be more relevant for clinical practice.
We are not aware of any studies of the time course and mech-
anism of interaction between probenecid and quinolones via
compartmental modeling with humans or animals.
Our primary objective was to describe the extent of the
interaction between gemifloxacin and probenecid using the
administration of multiple doses of probenecid. Our secondary
objective was to describe the time course and plausible mech-
anisms for the interaction between gemifloxacin and probene-
cid at the renal and nonrenal sites by compartmental modeling.
MATERIALS AND METHODS
Study design and drug administration. Seventeen healthy Caucasian subjects
(nine males and eight females) participated in the study. General clinical pro-
cedures were as previously described (18). The study was a randomized, con-
trolled, two-way crossover analysis. Subjects fasted from 12 h before until 3 h
after administration of gemifloxacin. In each of the two study periods, each
subject received a single oral dose of 320 mg gemifloxacin (Factive, 320-mg
tablets) either alone or with 4.5 g of probenecid (Probenecid Weimer, 500-mg
tablets) divided into eight oral doses. We intended to study the maximum extent
of interaction between probenecid and gemifloxacin. Therefore, we administered
relatively high doses of probenecid throughout the whole plasma gemifloxacin
concentration-time profile. Probenecid dosing was 1,000 mg at 10 h and 2 h
before the administration of gemifloxacin, followed by 250 mg at 6 h and 14 h af-
ter the administration of gemifloxacin and 500 mg at 24 h, 36 h, 48 h, and 60 h
after the administration of gemifloxacin. Doses of all drugs were given with 240
ml of low-carbonation, calcium-poor mineral water. Food and fluid intakes were
strictly standardized on each study day. The treatment periods were separated by
a washout period of at least 7 days. Subjects were requested to abstain from
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caffeine-containing foods and beverages, grapefruit products, orange juice, alco-
hol, and excessive exposure to sunlight during the study periods.
Sampling schedule. Blood samples were collected from a forearm vein by use
of an indwelling catheter immediately before the gemifloxacin dose and at 0.5, 1,
1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, and 48 h postdose. Urine samples were collected
before gemifloxacin administration and during the following time intervals: 0 to
4, 4 to 8, 8 to 12, 12 to 16, 16 to 24, 24 to 30, 30 to 36, 36 to 48, 48 to 60, and 60
to 72 h after the gemifloxacin dose. All samples were protected from daylight
throughout sample preparation and analysis. All samples were immediately fro-
zen and stored at 20°C until analysis.
Determination of plasma and urine drug concentrations. For determination of
plasma gemifloxacin and probenecid concentrations, 50 and 100 l, respectively,
of each sample were precipitated with 250 and 300 l, respectively, acetonitrile
containing the internal standard. After being thoroughly mixed, the samples were
centrifuged for approximately 15 min at 11,000  g for gemifloxacin samples or
5 min at 3,280  g for probenecid samples. From each human urine sample, 50 l
of the supernatant was diluted by 400 l of mobile phase containing the internal
standard. For the prepared plasma and urine samples, 10 l of each gemifloxacin
sample or 15 l of each probenecid sample was chromatographed on a reversed-
phase column by isocratic elution. The samples were analyzed by liquid chro-
matography-tandem mass spectrometry, with a selected reaction-monitoring
method. The reaction for gemifloxacin was precursor 3 product ion for gemi-
floxacin m/z 390 3 m/z 313 and for the internal standard m/z 394 3 m/z 313.
Both analyses were in the positive mode. Gemifloxacin and the internal standard
were eluted after approximately 1.1 min. Calibration was performed by weighted
(1/y2) linear regression.
The reaction for probenecid was precursor3 product ion for probenecid m/z
284 3 m/z 240 and for the internal standard m/z 329 3 m/z 205. Both analyses
were in the negative mode. Probenecid and the internal standard were eluted
after 1.4 and 0.8 min. Calibration was performed by weighted (1/x2) linear
regression. The MacQuan software (version 1.6 [1991 to 1998]; PE Sciex, Thorn-
hill, Ontario, Canada) was used for evaluation of chromatograms.
Calibration standards for plasma and urine were prepared by adding the
appropriate volume of a standard solution of gemifloxacin or probenecid or of
the more highly concentrated calibration standard solution to drug-free human
plasma or urine. No interferences were observed in plasma and urine for gemi-
floxacin, probenecid, or the internal standard. Calibration curves in plasma and
urine were linear between 0.0100 and 5.00 mg/liter for gemifloxacin and between
2.45 and 97.6 mg/liter for probenecid. The quantification limits were identical
with the lowest calibration levels. The interday precision and the analytical
recovery of the spiked quality control samples of gemifloxacin in human plasma
(urine) ranged from 3.7 to 7.2% (5.7 to 7.7%) and from 100.9 to 101.4% (98.1 to
103.3%), respectively. The interday precision and the analytical recovery of the
spiked quality control samples of probenecid in human plasma ranged from 5.1
to 5.8% and from 90.3 to 102.6%, respectively.
Computation. WinNonlin (version 4.0.1; Pharsight Corporation) was used for
NCA (as described previously [18]), compartmental modeling, and analysis of
variance statistics. NONMEM version V release 1.1 (NONMEM Project Group,
University of California, San Francisco) (4) was utilized for visual predictive
checks (5) and Monte Carlo simulation.
Compartmental modeling. All plasma and urine profiles for gemifloxacin (with
and without probenecid) and probenecid were modeled simultaneously in order
to derive the maximum amount of information from the data. Model discrimi-
nation, including visual predictive checks, was performed as reported previously
(19).
Absorption and disposition of gemifloxacin. One-, two-, and three-compart-
ment disposition models with first-order absorption and with or without an
absorption lag time were tested. The renal clearance of gemifloxacin was
CLR(fu  GFR)  VmaxR/KmR  	G
 where fu is the non-protein-bound
fraction of gemifloxacin in plasma, GFR is the glomerular filtration rate, VmaxR is
the maximum rate of the mixed-order renal elimination, KmR is the gemifloxacin
concentration associated with a half-maximal rate for the mixed-order renal
elimination of gemifloxacin, [G] is plasma gemifloxacin concentration, fu  GFR
is filtration clearance, and VmaxR/KmR  	G
 describes net tubular secretion.
Since the range of fu is between 0.3 and 0.4 (3) and all subjects had normal renal
function, the renal filtration clearance of gemifloxacin, fu  GFR, is about 2
liters/h and accounts for only about 6% of the total body clearance. Therefore,
the first-order component of renal clearance was fixed to 2 liters/h.
The nonrenal elimination of gemifloxacin was described as a first-order pro-
cess. For models with a mechanism-based interaction at the nonrenal site, the
nonrenal clearance was CLNR  VmaxNR/KmNR  	G
 where VmaxNR is the max-
imum rate of the nonrenal elimination and KmNR is the gemifloxacin concentra-
tion associated with the half-maximal rate of the mixed-order nonrenal elimina-
tion.
Absorption and disposition of probenecid. One- and two-compartment dispo-
sition models with parallel first-order and mixed-order elimination pathways
were tested, since saturable elimination of probenecid has been reported previ-
ously (9, 34). The oral absorption was described as a first-order process with or
without a lag time.
Interaction models. It was assumed that the first-order renal elimination (glo-
merular filtration) of gemifloxacin was not influenced by probenecid and that
probenecid interacts with the tubular secretion, with the nonrenal elimination, or
with both. These interactions were described as a competitive, uncompetitive, or
noncompetitive inhibition (Table 1). Alternatively, static interactions were ex-
pressed either as two different nonrenal clearances for gemifloxacin with and
without probenecid or as two different intercompartmental clearances.
The models with different combinations of interactions at the renal and non-
renal sites are shown in Table 2. For the competitive interactions, the relative
affinities (expressed as the ratio of the competitive inhibition constant [Kic] to the
Km) of gemifloxacin and probenecid to the transporter were calculated (Table 1),
with differences in molecular weight (389 g/mol for the gemifloxacin base and 285
g/mol for the probenecid base) being accounted for.
Ethics. The study was approved by the local ethics committee, and all subjects
gave their written informed consent prior to starting the study. The study was
conducted according to the revised version of the Declaration of Helsinki.
RESULTS
All 17 subjects completed the study. The average weight 
standard deviation was 69.1  13 kg, and the average height
was 173  10 cm. Gemifloxacin concentrations in plasma were
slightly higher for the treatment with probenecid (Fig. 1A),
and the amount of gemifloxacin excreted in urine (Fig. 1B) was
reduced by probenecid concentrations (Fig. 1C).
NCA. Addition of probenecid to gemifloxacin reduced the
median renal clearance from 13.1 to 6.49 liters/h (reduction by
51%, P  0.01) and the median nonrenal clearance from 24.2
to 19.0 liters/h (reduction by 19%, P  0.01). Therefore, total
body clearance was decreased by 31% (P  0.01). The median
TABLE 1. Mechanisms of inhibitiona
Type of inhibition
(inhibition constant) Apparent Km Apparent Vmax
Competitive (Kic) Km  {1  (	P
/Kic)} Vmax
Uncompetitive (Kiu) Km/{1  (	P
/Kiu)} Vmax/{1  (	P
/Kiu)}
Noncompetitive (Ki) Km Vmax/{1  (	P
/Ki)}
a 	P
, probenecid concentration. Kic describes the affinity of probenecid to the
drug transporter without gemifloxacin. Kiu describes the affinity of probenecid to
the transporter-gemifloxacin complex. Ki represents a special case in which
probenecid binds to both the free transporter and the transporter-gemifloxacin
complex with the same affinity (i.e., Ki  Kic  Kiu).
TABLE 2. Interaction models
Model
Inhibitiona of: No. of subjects
for which
model had
best AICb
Renal tubular
secretion
Nonrenal
clearance
Distributional
clearance
1 C S None 8
2 NC S None 2
3 UC S None 1
4 C C None 0
5 NC NC None 5
6 C S S 1
a C, competitive inhibition; NC, noncompetitive inhibition; UC, uncompetitive
inhibition (Table 1); S, static inhibition (two different parameters for treatment
with and without probenecid).
b AIC, Akaike information criterion.
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terminal half-life of gemifloxacin in plasma was increased from
8.09 to 9.49 h (22%, P  0.01) with probenecid.
Compartmental modeling. A two-compartment disposition
model with a lag time was selected for gemifloxacin, and a
one-compartment model with a lag time was selected for pro-
benecid. The Akaike information criterion (data not shown)
and the visual predictive checks showed that model 1 had the
best predictive performance among the tested interaction
models (Table 2 and Fig. 2). This suggested a competitive
inhibition of the renal tubular secretion of gemifloxacin by
probenecid as the most likely mechanism. Table 3 lists the
average pharmacokinetic parameters of gemifloxacin for
model 1.
After we accounted for differences in molecular weight, the
affinity of gemifloxacin to the renal tubular transporter was
10-fold higher than that of probenecid. Since probenecid
reached an 200-fold-higher area under the molar concentra-
tion-time curve from 0 to 24 h than probenecid (Fig. 1), pro-
benecid inhibited the secretion of gemifloxacin at the renal
transporter.
Monte Carlo simulations suggested that the gemifloxacin
area under the concentration-time curve (0 to 24 h) is in-
creased by 20% (median) when gemifloxacin is given together
with clinically relevant doses of probenecid (500 mg twice
daily).
DISCUSSION
The interaction with probenecid has been studied for a long
time and for many quinolones and beta-lactams. The extent of
interaction with probenecid may reach clinical significance for
drugs which display active tubular secretion (12, 21, 33). Re-
duced renal clearance with probenecid has been reported
for several quinolones, e.g., norfloxacin (25), fleroxacin (23),
enoxacin (35), ciprofloxacin (14), levofloxacin (10, 11), and
gatifloxacin (21). Moxifloxacin and sparfloxacin were not af-
fected by probenecid (24, 28).
In the vast majority of studies, the interaction with probe-
necid is studied at the renal site. Less is known about the
interaction of probenecid with drugs at other sites in the body.
Probenecid interacts with both OATs and OCTs that are in-
volved in the active renal secretion of drug molecules (13), and
they have been found at various other sites in the body (20, 26).
Recently, probenecid was shown to affect active transport pro-
cesses at the blood-brain barrier (6). The importance of drug
transporters in hepatocytes has been highlighted by Cummins
et al. (8). Through the influence of probenecid on drug trans-
porters in the hepatocytes or enterocytes, an influence of pro-
benecid on the nonrenal elimination and metabolism of drugs
seems likely. In humans, probenecid decreases the renal ex-
FIG. 1. Gemifloxacin and probenecid concentrations in plasma and amounts in urine (averages  standard deviations).
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cretion of paracetamol glucuronide by 79% (15) and also in-
creases the biotransformation of carbamazepine (17).
The renal elimination of unchanged gemifloxacin accounts
for 20 to 40% of the dose. Most of the dose is eliminated via
other routes, which offers various possibilities for an interac-
tion with probenecid at the nonrenal site(s). As a zwitterion at
physiological pH values (pKa1  6.5, pKa2  8.9), gemifloxacin
might be able to interact with both OATs and OCTs (27).
Cimetidine, an inhibitor of the organic cationic renal transport,
decreases the renal clearance of gemifloxacin by 28% (1).
We studied the interaction between gemifloxacin and pro-
benecid. Compartmental modeling of plasma and urine pro-
files of gemifloxacin and probenecid simultaneously showed
that a model with competitive interaction at the renal site and
FIG. 2. Visual predictive check for plasma concentrations of gemifloxacin with and without probenecid for model 1 (Table 2). The plots show
the observed data, the 80% prediction intervals (10th to 90th percentiles), and the interquartile range (25th to 75th percentiles). Ideally, 50% of
the observed data points should fall inside the interquartile range and 80% of the observed data should fall inside the 80% prediction interval at
each time point.
TABLE 3. Pharmacokinetic parameter estimates and between-subject variability for gemifloxacin for model 1d
With or without
probenecid
Avg (% coefficient of variation) for gemifloxacina
Ka (h1) Tlag (h)
CLNR
(liters h1)
KmR(mg liter1)
VmaxR(mg h1)
CLR
(liters h1)
Kic
(mg liter1) V1 (liters) V2 (liters)
CLIC
(liters h1)
With probenecid 0.897 (104) 0.129 (104) 21.0 (23)b
9.16 (20) 113 (21) 2c 69.3 (26) 89.5 (62) 160 (31) 39.8 (58)
Without probenecid 0.839 (62) 0.223 (104) 25.2 (26)b
a Ka, absorption rate constant; Tlag, absorption lag time; CLNR, apparent nonrenal clearance; V1, apparent volume of distribution of central compartment; V2,
apparent volume of distribution of peripheral compartment; CLIC, apparent intercompartmental clearance. Only for Ka, Tlag, and CLNR, two parameters were allowed
within subjects for gemifloxacin with and without probenecid.
b Values are significantly different (P  0.01).
c Fixed, not estimated.
d See Table 2 for model 1.
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static interaction at the nonrenal site had the best predictive
performance of the tested models. As the extent of inhibition
at the nonrenal site was much smaller than at the renal site, a
specific mechanism could not be identified for the nonrenal
interaction. Therefore, our final model had a competitive in-
teraction at the renal site and a static interaction at the non-
renal site. Also, from the physiological point of view, a com-
petitive mechanism seems the most reasonable, as it describes
a situation in which gemifloxacin and probenecid compete for
the same active site of the renal tubular transporter.
It was recently pointed out that information about renal
transport processes of quinolones is important, e.g., to explore
potential toxicities due to administration of quinolones with
other drugs, such as methotrexate (32). While from our mod-
eling no conclusions can be drawn about which particular
transporters are involved in the studied interaction, the model
proposed here can predict the extent of the interaction for
dosage regimens other than those studied. Drug interactions at
the tubular secretion site are frequently reported, and our
model can be utilized as the basis for models for other drugs
and drug groups.
In a recent overview of the quinolone renal transport liter-
ature, studies were cited suggesting the involvement of both
OATs and OCTs for ciprofloxacin, norfloxacin, ofloxacin,
enoxacin, enrofloxacin, fleroxacin, pefloxacin, and levofloxacin
(32). Both OAT1 and OAT3 were previously identified for
renal uptake of carboxyfluoroquinolones (29, 30, 32). Levo-
floxacin was shown to inhibit OCT2 (22). It was suggested that
zwitterionic quinolones such as ofloxacin, levofloxacin, and
gemifloxacin can interact with both OATs and OCTs. VanWert
et al. (32) found that ciprofloxacin was transported by OAT3
and that ciprofloxacin, norfloxacin, ofloxacin, and gatifloxacin
inhibited OAT3. Ciprofloxacin did not interact with OAT1,
while probenecid inhibited both OAT1 and OAT3. In the
absence of information about specific transporters interacting
with gemifloxacin, it seems likely that OATs, OCTs, or both
are involved in the interaction between gemifloxacin and pro-
benecid. For probenecid and also several quinolones, interac-
tions have been reported with OAT1, OAT3, and OCTs.
We are not aware of any reports of a mechanism-based
model for the interaction of quinolones and probenecid in
humans or animals. As most quinolones are eliminated via
tubular secretion, the competitive inhibition of renal tubular
secretion that we found for gemifloxacin with probenecid could
also apply to other quinolones.
In conclusion, modeling suggested a competitive inhibition
of the renal tubular secretion of gemifloxacin by probenecid.
Based on the molar ratio, the affinity to the renal transporter
was 10-fold higher for gemifloxacin than for probenecid, but
probenecid inhibited the secretion of gemifloxacin because
probenecid reached an 200 times-higher average area under
the molar concentration-time curve from 0 to 24 h than gemi-
floxacin. Future mechanistic studies for other quinolones are
required to further explore this mechanism of interaction.
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